Results 201 to 210 of about 98,202 (223)

Wenshen Zhuanggu Fang reduces breast cancer bone metastasis by regulating macrophage polarization: a bioinformatics analysis combined with experimental validation. [PDF]

J Tradit Chin Med
Yang Z, Youyang S, Xiaofei L, Rui Y, Qiong LI, Feifei LI, Xiaojuan Y, Yi W, Chenping S, Xianghui H, Sheng L.   +10 more
europepmc   +1 more source

Mechanisms of enhancer‐driven oncogene activation

International Journal of Cancer, Volume 158, Issue 2, Page 333-341, 15 January 2026.
Abstract An aggressive subtype of acute myeloid leukemia (AML) is caused by enhancer hijacking resulting in MECOM overexpression. Several chromosomal rearrangements can lead to this: the most common (inv(3)/t(3;3)) results in a hijacked GATA2 enhancer, and there are several atypical MECOM rearrangements involving enhancers from other hematopoietic ...
Joyce Vriend, Ruud Delwel, Dorien Pastoors   +2 more
wiley   +1 more source

Targeting menin in lysine methyltransferase 2A/nucleophosmin-mutated leukemia: A novel strategy from epigenetic dysregulation to clinical therapy (Review). [PDF]

Oncol Lett
Bi J, Zhou H.
europepmc   +1 more source

Enhancer‐dependent gene regulation in space, time, and malignancies

International Journal of Cancer, Volume 158, Issue 2, Page 357-367, 15 January 2026.
Abstract Control of cell‐type‐specific gene activation requires the coordinated activity of distal regulatory elements, including enhancers, whose inputs must be temporally integrated. Dysregulation of this regulatory capacity, such as aberrant usage of enhancers, can result in malignant transformation of cells.
Belinda Blum, Victoria Dachtler, Angelika Feldmann   +2 more
wiley   +1 more source

Exportin 1 as a Therapeutic Target to Overcome Drug Resistance in Lung Cancer. [PDF]

Cells
Di Marco MV, Gasparetto A, Chiarle R, Voena C.   +3 more
europepmc   +1 more source

Deregulated enhancer‐promoter communication in cancer through altered nuclear architecture

International Journal of Cancer, Volume 158, Issue 2, Page 409-422, 15 January 2026.
Abstract Enhancers are critical regulators of gene expression. Structural variations in cancer genomes can lead to enhancer hijacking, where oncogenes are activated by mistargeted enhancer activity. Novel enhancer‐promoter interactions may also arise through chromosomal rearrangements that create extrachromosomal DNA elements.
Isabelle Seufert, Claire Vargas, Sina Jasmin Wille, Karsten Rippe   +3 more
wiley   +1 more source

Population-wide introduction of dose-adjusted EPOCH-R in high-grade B-cell lymphoma with MYC/BCL2 rearrangements, DLBCL morphology. [PDF]

Blood Adv
Alduaij W, Sehn LH, Champagne JN, Collinge B, Ben-Neriah S, Jiang A, Hilton LK, Boyle M, Meissner B, Slack GW, Farinha P, Craig JW, Savage KJ, Villa D, Gerrie AS, Freeman CL, Mungall AJ, Steidl C, Scott DW.   +18 more
europepmc   +1 more source

Epigenetic reprogramming in multiple myeloma—Challenges and opportunities

International Journal of Cancer, Volume 158, Issue 2, Page 423-432, 15 January 2026.
Abstract In cancer, mutational processes act in concert with epigenetic reprogramming to endow malignant cells with hallmark properties that underpin tumorigenesis. Compared with the relatively rigid and slow processes of genetic evolution, the plastic nature of chromatin enables cells to adapt to a changing environment more rapidly.
Subhasree Kumar, Lev M. Kats, Emily Gruber   +2 more
wiley   +1 more source

LL22NC03-N14H11.1 regulates the m6A modification of MYC and promotes glycolytic activity in hepatocellular carcinoma cells by inhibiting IGF2BP3 ubiquitination degradation. [PDF]

J Exp Clin Cancer Res
Yi T, He J, Pan M, Wang Y, Lin C, Ye Y, Yang W, Ye X, Ning D, Lan J, Huang J, Tan S, Li H, Wei Z, Yuan C.   +14 more
europepmc   +1 more source

From the Editor's desk...: March 2016 [PDF]

, 2016
Bataller, R, Berg, T, Jalan, R, Moreau, R, Zucman-Rossi, J   +4 more
core